Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Feb 10 04:00PM ET
1.28
Dollar change
-0.09
Percentage change
-6.57
%
Index- P/E- EPS (ttm)-0.70 Insider Own2.53% Shs Outstand78.58M Perf Week-13.51%
Market Cap100.59M Forward P/E- EPS next Y-0.45 Insider Trans0.00% Shs Float76.59M Perf Month34.68%
Income-32.28M PEG- EPS next Q-0.11 Inst Own6.89% Short Float11.75% Perf Quarter10.34%
Sales0.00M P/S- EPS this Y59.95% Inst Trans-12.01% Short Ratio3.31 Perf Half Y6.67%
Book/sh0.25 P/B5.19 EPS next Y15.53% ROA-186.64% Short Interest9.00M Perf Year75.34%
Cash/sh0.27 P/C4.76 EPS next 5Y29.48% ROE-535.10% 52W Range0.66 - 1.84 Perf YTD23.08%
Dividend Est.- P/FCF- EPS past 5Y61.44% ROI-203.12% 52W High-30.43% Beta2.41
Dividend TTM- Quick Ratio2.26 Sales past 5Y28.29% Gross Margin- 52W Low94.82% ATR (14)0.19
Dividend Ex-DateMar 24, 2011 Current Ratio2.26 EPS Y/Y TTM54.63% Oper. Margin- RSI (14)52.31 Volatility12.10% 16.86%
Employees16 Debt/Eq0.04 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price5.83
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q68.15% Payout- Rel Volume1.09 Prev Close1.37
Sales Surprise- EPS Surprise21.07% Sales Q/Q- EarningsNov 13 AMC Avg Volume2.72M Price1.28
SMA204.79% SMA5016.72% SMA2004.89% Trades Volume2,972,553 Change-6.57%
Date Action Analyst Rating Change Price Target Change
Jul-21-21Initiated Cantor Fitzgerald Overweight $18
Nov-01-18Initiated Oppenheimer Outperform
Apr-02-18Initiated H.C. Wainwright Buy $11
Mar-19-18Upgrade Maxim Group Hold → Buy $13
Jan-28-25 03:11PM
Jan-23-25 08:10AM
Jan-08-25 08:20AM
Jan-02-25 08:00AM
Dec-10-24 08:30AM
08:45AM Loading…
Dec-09-24 08:45AM
Nov-28-24 05:37AM
Nov-27-24 08:45AM
Nov-13-24 04:15PM
Nov-05-24 09:55AM
Oct-15-24 08:45AM
Oct-10-24 04:05PM
Sep-18-24 03:09PM
Aug-13-24 04:10PM
Aug-06-24 08:45AM
08:30AM Loading…
Jul-31-24 08:30AM
Jul-16-24 09:05AM
Jul-08-24 08:45AM
Jun-24-24 09:05AM
Jun-17-24 09:45AM
09:05AM
Jun-10-24 08:40AM
May-14-24 10:54PM
04:05PM
May-01-24 08:35AM
Apr-29-24 08:45AM
Mar-28-24 10:54PM
04:05PM
07:00AM
Mar-26-24 07:35AM
04:05PM Loading…
Mar-19-24 04:05PM
08:47AM
Mar-15-24 09:00AM
Mar-08-24 08:00AM
Mar-01-24 08:30AM
Feb-29-24 08:00AM
Feb-06-24 08:30AM
Jan-25-24 08:45AM
Jan-11-24 06:00AM
Jan-10-24 11:30AM
Jan-09-24 08:30AM
Jan-04-24 09:01AM
08:41AM
Jan-03-24 08:05PM
07:30AM
Dec-27-23 08:55AM
Dec-21-23 08:15AM
Dec-14-23 08:30AM
Dec-13-23 08:30AM
Dec-04-23 08:47AM
Nov-29-23 08:45AM
Nov-13-23 08:50AM
Nov-09-23 04:04PM
Nov-06-23 08:57AM
Oct-31-23 08:05AM
Oct-30-23 09:03AM
Oct-17-23 08:45AM
Oct-16-23 08:45AM
Oct-12-23 04:05PM
Oct-11-23 08:30AM
Oct-10-23 04:15PM
07:00AM
Sep-21-23 08:30AM
Sep-18-23 04:19PM
Aug-22-23 08:30AM
Aug-10-23 04:08PM
Jul-15-23 09:25AM
Jun-28-23 04:00PM
08:30AM
Jun-22-23 08:45AM
Jun-15-23 04:05PM
Jun-13-23 08:30AM
May-25-23 05:05PM
May-16-23 08:30AM
May-11-23 04:12PM
May-04-23 08:30AM
Apr-26-23 04:01PM
Apr-20-23 08:30AM
Apr-18-23 08:30AM
Mar-16-23 04:11PM
Mar-07-23 08:30AM
Feb-24-23 08:42AM
08:30AM
07:29AM
Feb-23-23 04:01PM
Feb-05-23 07:57AM
Jan-19-23 08:30AM
Jan-05-23 08:30AM
Dec-13-22 02:49PM
08:30AM
Dec-08-22 08:30AM
Dec-06-22 08:30AM
Dec-01-22 08:30AM
Nov-30-22 08:30AM
Nov-16-22 05:28AM
Nov-14-22 01:25PM
08:15AM
07:50AM
Nov-10-22 11:09AM
08:30AM
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.